[go: up one dir, main page]

WO2009071691A3 - Dérivés oxindoliques et leur utilisation comme médicament - Google Patents

Dérivés oxindoliques et leur utilisation comme médicament Download PDF

Info

Publication number
WO2009071691A3
WO2009071691A3 PCT/EP2008/066937 EP2008066937W WO2009071691A3 WO 2009071691 A3 WO2009071691 A3 WO 2009071691A3 EP 2008066937 W EP2008066937 W EP 2008066937W WO 2009071691 A3 WO2009071691 A3 WO 2009071691A3
Authority
WO
WIPO (PCT)
Prior art keywords
medication
oxindole derivatives
derivatives
oxindole
vasopressin
Prior art date
Application number
PCT/EP2008/066937
Other languages
German (de)
English (en)
Other versions
WO2009071691A2 (fr
Inventor
Astrid Netz
Thorsten Oost
Hervé Geneste
Wilfried Braje
Wolfgang Wernet
Liliane Unger
Wilfried Hornberger
Wilfried Lubisch
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of WO2009071691A2 publication Critical patent/WO2009071691A2/fr
Publication of WO2009071691A3 publication Critical patent/WO2009071691A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés oxindoliques substitués, des produits pharmaceutiques contenant ces dérivés et leur utilisation dans le traitement de maladies vasopressine-dépendantes.
PCT/EP2008/066937 2007-12-07 2008-12-05 Dérivés oxindoliques et leur utilisation comme médicament WO2009071691A2 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US1223407P 2007-12-07 2007-12-07
US1225107P 2007-12-07 2007-12-07
US1224107P 2007-12-07 2007-12-07
US1226507P 2007-12-07 2007-12-07
US61/012,241 2007-12-07
US61/012,234 2007-12-07
US61/012,265 2007-12-07
US61/012,251 2007-12-07
US5651908P 2008-05-28 2008-05-28
US61/056,519 2008-05-28

Publications (2)

Publication Number Publication Date
WO2009071691A2 WO2009071691A2 (fr) 2009-06-11
WO2009071691A3 true WO2009071691A3 (fr) 2009-11-12

Family

ID=40626778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/066937 WO2009071691A2 (fr) 2007-12-07 2008-12-05 Dérivés oxindoliques et leur utilisation comme médicament

Country Status (1)

Country Link
WO (1) WO2009071691A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573836A (zh) * 2009-06-10 2012-07-11 雅培股份有限两合公司 取代的羟吲哚衍生物治疗和预防疼痛的应用
MX2015012393A (es) 2013-03-14 2016-04-28 Abbvie Deutschland Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.
US9840495B2 (en) 2013-12-20 2017-12-12 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
US9862704B2 (en) 2013-12-20 2018-01-09 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases
US9527856B2 (en) 2014-05-15 2016-12-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018105A1 (fr) * 1993-12-24 1995-07-06 Sanofi Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine
US20040180878A1 (en) * 2001-07-17 2004-09-16 Alain Di Malta Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
WO2005030755A1 (fr) * 2003-09-30 2005-04-07 Abbott Gmbh & Co. Kg Derives heteroaryle-substitues de 1,3-dihydroindol-2-one et medicaments renfermant ceux-ci
WO2006005609A2 (fr) * 2004-07-13 2006-01-19 Abbott Gmbh & Co.Kg Derives d'oxindole substitues, et medicaments les renfermant
WO2006100081A2 (fr) * 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Derives d'indoxyle substitues, medicaments les contenant et leur utilisation
WO2006100080A1 (fr) * 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Derives d'indoxyle substitues, medicaments les contenant et leur procede de production
WO2008080971A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivé d'oxindole substitué et son utilisation comme ligand du récepteur de la vasopressine
WO2008080972A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivé d'oxindole substitué et son utilisation comme modulateur du récepteur de la vasopressine
WO2008080973A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivés d'oxindole substitués et leur utilsiation comme lignads du récepteur de la vasopressine
WO2008080970A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivé d'oxindole substitué et son utilisation comme ligand du récepteur de la vasopressine

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018105A1 (fr) * 1993-12-24 1995-07-06 Sanofi Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine
US20040180878A1 (en) * 2001-07-17 2004-09-16 Alain Di Malta Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
WO2005030755A1 (fr) * 2003-09-30 2005-04-07 Abbott Gmbh & Co. Kg Derives heteroaryle-substitues de 1,3-dihydroindol-2-one et medicaments renfermant ceux-ci
WO2006005609A2 (fr) * 2004-07-13 2006-01-19 Abbott Gmbh & Co.Kg Derives d'oxindole substitues, et medicaments les renfermant
WO2006100081A2 (fr) * 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Derives d'indoxyle substitues, medicaments les contenant et leur utilisation
WO2006100080A1 (fr) * 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Derives d'indoxyle substitues, medicaments les contenant et leur procede de production
WO2008080971A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivé d'oxindole substitué et son utilisation comme ligand du récepteur de la vasopressine
WO2008080972A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivé d'oxindole substitué et son utilisation comme modulateur du récepteur de la vasopressine
WO2008080973A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivés d'oxindole substitués et leur utilsiation comme lignads du récepteur de la vasopressine
WO2008080970A1 (fr) * 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivé d'oxindole substitué et son utilisation comme ligand du récepteur de la vasopressine

Also Published As

Publication number Publication date
WO2009071691A2 (fr) 2009-06-11

Similar Documents

Publication Publication Date Title
NO20090295L (no) Substituerte heteroarylderivater
WO2008132139A3 (fr) Nouveaux dérivés hétérocycliques utiles pour le traitement des troubles du système nerveux central
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2009142571A8 (fr) Dérivés d'indazoles à substitutions phényle et benzodioxinyle
WO2005075425A3 (fr) Derives de bisaryluree
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
WO2006100081A3 (fr) Derives d'indoxyle substitues, medicaments les contenant et leur utilisation
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2008006795A3 (fr) Composés d'indole
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
TW200612936A (en) Indole derivatives
WO2006077024A3 (fr) Derives de 5-aminoindole
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2010052144A3 (fr) Agonistes du récepteur 2 de neuropeptide (y-2r) et leurs utilisations
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
TW200738627A (en) Trialkylsilyl-indoles
WO2008074833A3 (fr) Composés
WO2007130821A3 (fr) Modulateurs des récepteurs de mglur5 ii
WO2006072458A3 (fr) Derives d'oxindol substitues, agents pharmaceutiques les contenant, et leur utilisation
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
WO2006134021A3 (fr) Procede de preparation de nouveaux sels de tiotropium, nouveaux sels de tiotropium en tant que tels et compositions pharmaceutiques associees

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856805

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08856805

Country of ref document: EP

Kind code of ref document: A2